Osteosarcoma, a primary bone cancer, often shows limited and inconsistent responses to immune checkpoint inhibitors. Researchers attribute this treatment challenge to the tumor's highly immunosuppressive microenvironment, which prevents the immune system from mounting an effective attack against cancer cells.
Recent research published in Frontiers explores how nutritional biomarkers influence and regulate the tumor immune microenvironment in osteosarcoma. By analyzing these biomarkers, scientists are gaining insight into the metabolic and nutritional factors that shape immune suppression around tumors.
Additionally, the findings suggest that nutritional biomarkers could act as predictors for patient response to immune checkpoint inhibitor therapies. Identifying these markers may assist oncologists in evaluating treatment efficacy and developing more personalized immunotherapy approaches for individuals fighting osteosarcoma.
Source Attribution: Article content originally reported by Ren; Haoyang; Shen; Chengchun. Read original story coverage on Ren; Haoyang; Shen; Chengchun →
